Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients

British Journal of Haematology, Journal Year: 2023, Volume and Issue: 201(5), P. 813 - 823

Published: April 3, 2023

Immunocompromised patients, such as those with a haematological malignancy, are at higher risk of SARS-CoV-2 infection, severe outcomes and mortality. Tixagevimab/cilgavimab is monoclonal antibody combination which binds to the spike protein. The PROVENT phase III clinical trial reported that tixagevimab/cilgavimab prophylaxis significantly reduced COVID-19 infection in immunocompromised participants. However, was conducted before Omicron variant became prevalent. This systematic review meta-analysis provide an up-to-date summary real-world effectiveness including patients malignancies. Clinical studies from 1 January 2021 October 2022, breakthrough infections after tixagevimab/cilgavimab, were included. COVID-19-related hospitalisations, intensive care admissions mortality also assessed. A performed ascertain overall effectiveness. Eighteen studies, 25 345 participants, 5438 pathologies, included review. against hospitalisation, admission COVID-19-specific 40.54%, 66.19%, 82.13% 92.39%, respectively. highlights reducing for immunosuppressed individuals, during Omicron-predominant era. Real-world important ongoing certainty benefit new variants.

Language: Английский

---

A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)

Antibodies, Journal Year: 2023, Volume and Issue: 12(1), P. 5 - 5

Published: Jan. 11, 2023

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of SARS-CoV-2 variants raised concerns about these therapies’ efficacy and long-term viability. Studies reported several antibodies, that received authorization COVID-19 treatment, not effective against new or subvariants SARS-CoV-2, hence their distribution has to be paused. Here, authors reviewed status currently available monoclonal potential as therapeutic agent, challenges ahead. To address issues, presented general information on how work SARS-CoV-2. The then focus have been deployed current status, well evidence supporting an early intervention Lastly, discussed some leading obstacles hinder development administration

Language: Английский

---

Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience

Viruses, Journal Year: 2022, Volume and Issue: 15(1), P. 118 - 118

Published: Dec. 30, 2022

Effective treatments and vaccines against COVID-19 used in clinical practice have made a positive impact on controlling the spread of pandemic, where they are available. Nevertheless, even if fully vaccinated, immunocompromised patients still remain at high risk adverse outcomes. This has driven largely expanding field monoclonal antibodies, with variable results. Tixagevimab/Cilgavimab (AZD7442), long-acting antibody combination that inhibits attachment SARS-CoV-2 spike protein to surface cells, proved promising reducing incidence symptomatic or death high-risk individuals without major events when given as prophylaxis, well early treatment. Real-world data confirm combination’s prophylaxis efficacy lowering incidence, hospitalization, mortality associated solid organ transplant recipients, immune-mediated inflammatory diseases hematological malignancies, B-cell-depleting therapies. Data suggest difference neutralization efficiency between subtypes favor BA.2 over BA.1. In treating COVID-19, AZD7442 showed significant reduction severe cases course disease, within 5 days symptom onset, being events, it is addition standard care. The possibility development spike-protein mutations resist antibodies been reported; therefore, increased vigilance required view evolving variants. may be powerful ally preventing individuals. Further research include more groups assess concerns limiting its use, along evolutionary trajectory.

Language: Английский

---

SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Aug. 28, 2023

Introduction The COVID-19 pandemic is a major global public health crisis. More than 2 years into the pandemic, effective therapeutic options remain limited due to rapid viral evolution. Stemming from emergence of multiple variants, several monoclonal antibodies are no longer suitable for clinical use. This scoping review aimed summarize preclinical and evidence bebtelovimab in treating newly emerging SARS-CoV-2 variants. Methods We systematically searched five electronic databases (PubMed, CENTRAL, Embase, Global Health, PsycINFO) date inception September 30, 2022, studies reporting on effect infection, using combination search terms around ―bebtelovimab‖, ―LY-CoV1404‖, ―LY3853113‖, ―coronavirus infection‖. All citations were screened independently by two researchers. Data extracted thematically analyzed based study design adhering stipulated approaches. Results Thirty-nine included, thirty-four non-clinical narratively synthesized, meta-analyzed. revealed not only potently neutralized wide-type existing variants concern such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), but also retained appreciable activity against Omicron lineages, including BA.2.75, BA.4, BA.4.6, BA.5. Unlike other antibodies, was able bind epitope S protein exploiting loop mobility or minimizing side-chain interactions. Pooled analysis depicted that rates hospitalization, ICU admission, death similar between therapies. Bebtelovimab associated with low incidence treatment-emergent adverse events. Conclusion Preclinical suggests be potential treatment amidst has comparable efficacy therapies without evident safety concerns.

Language: Английский

---

Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence

Expert Opinion on Drug Discovery, Journal Year: 2023, Volume and Issue: 18(3), P. 231 - 245

Published: Jan. 17, 2023

Direct-acting SARS-CoV-2 antiviral monoclonal antibodies have been an integral part of therapeutic strategies against COVID-19 pandemic. The strategy was jeopardized by the emergence new variants and resistant strains, making many quickly obsolete. Nevertheless, a possible consists in use antibody cocktails development cilgavimab + tixagevimab combination is placed this context.In review, we describe cocktail, from pre-clinical to real-world evidence.The clinical followed similar path that developed earlier stages Both convalescent plasma shown be effective trials prophylaxis early therapy. This cocktail has found its position therapy especially immunocompromised subjects for whom vaccine prevention not feasible. strategy, together with more stable pandemic situation, could ensure certain longevity drug resistance, when compared other antibodies. Recently emerged Omicron sub-lineages demonstrated ability escape cocktail's activity so future treatment compromised.

Language: Английский

---

COVID-19 prophylaxis: half-full or half-empty glass?

Blood, Journal Year: 2023, Volume and Issue: 141(2), P. 130 - 132

Published: Jan. 12, 2023

Language: Английский

---

Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study

Journal of Clinical Virology, Journal Year: 2022, Volume and Issue: 159, P. 105374 - 105374

Published: Dec. 30, 2022

Language: Английский

---

Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan

Journal of Infection and Chemotherapy, Journal Year: 2024, Volume and Issue: 31(1), P. 102467 - 102467

Published: July 9, 2024

Language: Английский

---

Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients

Medicina Clínica (English Edition), Journal Year: 2024, Volume and Issue: 163(6), P. 275 - 280

Published: Sept. 1, 2024

Language: Английский

---